1. Pink Sheet
  2. >>Geography

Bluebird Bio Withdraws Zynteglo From Germany Over Pricing

Germany Is The Only Country Where the Gene Therapy Was Marketed

 
• By Francesca Bruce

After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.

Bluebird bio
pricing concerns promt bluebird to pull Zynteglo from Germany • Source: Alamy

Price negotiations for bluebird bio’s gene therapy Zynteglo in Germany have failed and the company is withdrawing the high-cost product from the market. Not only is Germany the first country where the one-time gene therapy for treating transfusion-dependent beta-thalassaemia (TDT) was launched, it is also currently the only EU country where the treatment had been given to patients outside of a clinical trial setting.

Zynteglo has not been approved in any other markets worldwide. It is bluebird’s first product and will serve as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.